FindTrial
Sign In

Pridopidine

DRUG9 trials

Sponsors

Prilenia, Merit E. Cudkowicz, MD

Conditions

Amyotrophic Lateral SclerosisHuntington DiseaseHuntington's DiseaseParkinson Disease

Phase 2

Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease
CompletedNCT01306929
PrileniaHuntington Disease
Start: 2011-03-24End: 2018-01-05Updated: 2022-02-09
A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease
CompletedNCT02006472
PrileniaHuntington's Disease
Start: 2014-02-28End: 2016-07-07Updated: 2021-07-19
A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's Disease
TerminatedNCT02494778
PrileniaHuntington's Disease
Start: 2015-09-24End: 2018-01-12Updated: 2021-09-17
A Study to Assess the Safety and Effectiveness of Pridopidine Compared to Placebo in the Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson's Disease
TerminatedNCT03922711
PrileniaParkinson Disease
Start: 2019-05-22End: 2020-07-22Updated: 2022-07-01
HEALEY ALS Platform Trial - Master Protocol
RecruitingNCT04297683
Merit E. Cudkowicz, MDAmyotrophic Lateral Sclerosis
Start: 2020-06-14End: 2028-08-01Target: 1500Updated: 2026-03-27
HEALEY ALS Platform Trial - Regimen D Pridopidine
CompletedNCT04615923
Merit E. Cudkowicz, MDAmyotrophic Lateral Sclerosis
Start: 2020-12-18End: 2022-07-14Updated: 2023-08-23

Phase 3

PRidopidine's Outcome On Function in Huntington Disease, PROOF- HD
CompletedNCT04556656
PrileniaHuntington Disease
Start: 2020-10-16End: 2024-03-21Updated: 2025-03-12
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS
RecruitingNCT07322003
PrileniaAmyotrophic Lateral Sclerosis
Start: 2026-02-01End: 2029-03-01Target: 500Updated: 2026-02-27

Unknown Phase

A Second Intermediate-Size Expanded Access Protocol (EAP) for Pridopidine in People With Amyotrophic Lateral Sclerosis (Pridopidine EAP 2)
NCT06069934
PrileniaAmyotrophic Lateral Sclerosis
Updated: 2025-05-18

Related Papers

Long-Term Slowing of Progression in Huntington's Disease with Pridopidine Treatment
2026-02-17
Pridopidine in early-stage manifest Huntington's disease: a phase 3 trial.
2025-09-053 citations
Efficacy and Safety of Zilucoplan in Amyotrophic Lateral Sclerosis
JAMA Network Open2025-02-1711 citations
Pridopidine in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial.
2025-02-178 citations
CNM-Au8 in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial.
2025-02-176 citations
Verdiperstat in Amyotrophic Lateral Sclerosis: Results From the Randomized HEALEY ALS Platform Trial.
2025-02-176 citations
Cognitive impairment predicts medication discrepancies in Huntington's Disease: patient self-report compared to pharmacy records.
2024-12-121 citations
Results from the first four regimens of the HEALEY ALS Platform Trial (PL5.004)
Neurology2023-04-254 citations
Pridopidine Does Not Significantly Prolong the QTc Interval at the Clinically Relevant Therapeutic Dose
Neurology and Therapy2023-02-223 citations
Motor Neuron Disease Systematic Multi-Arm Adaptive Randomised Trial (MND-SMART): a multi-arm, multi-stage, adaptive, platform, phase III randomised, double-blind, placebo-controlled trial of repurposed drugs in motor neuron disease
BMJ Open2022-07-0134 citations
Characterizing patient compliance over six months in remote digital trials of Parkinson's and Huntington disease.
2018-12-2032 citations
Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study.
2018-12-1583 citations
Huntington’s Disease Clinical Trials Corner: August 2018
Journal of Huntington s Disease2018-06-0131 citations
Huntington’s Disease Clinical Trials Corner: February 2018
2018-01-0144 citations